Oxygen Biotherapeutics hires leader for new product division
This article was originally published in Clinica
Executive Summary
Oxygen Biotherapeutics (Costa Mesa, California), a company that is commercialising innovative medical devices and pharmaceuticals in the field of oxygen therapeutics and continuous substrate monitoring, has appointed Robert Diegelmann head of the company’s new wound care division. Dr Diegelmann is professor of biochemistry and molecular biology, anatomy and emergency medicine at Virginia Commonwealth University (VCU) Medical Center. He is already familiar with the company’s Oxycyte product for wound care and is considered to be a specialist in the field: “I view Bob Diegelmann as VCU’s wound care guru and I’m thrilled that he has contracted to be in charge of getting our topical and clinical wound indications to market,” said the company’s chairman and CEO, Chris Stern. The company’s priority market is therapeutics for traumatic brain injury.